A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2022-08-14
Target enrollment:
Participant gender:
Summary
This study is a multicenter phase I/II study of the treatment of patients with metastatic
prostate cancer. The objective of Phase I part is to study the safety and tolerability of
LAE001 monotherapy in patients with metastatic castration-resistant prostate cancer, and
determine the maximum tolerated dose (MTD) as well as the recommended phase II dose (RP2D) of
the drug, the Phase II part is to assess the efficacy of LAE001 in prolonging the
failure-free survival (FFS) of patients with metastatic castration-sensitive prostate cancer.